NMDP BioTherapies Unveils Enhanced Cellular Materials for Allogeneic Cell Therapy Advancement

Wednesday, April 17, 2024

NMDP BioTherapies, formerly Be The Match BioTherapies, has recently announced significant upgrades to its cellular starting material offerings, including the addition of a Drug Master File (DMF) to its standard GMP leukopak for faster regulatory filings. These improvements aim to meet the changing needs of the allogeneic cell therapy industry, focusing on quicker delivery times, customizable options, and expanded capabilities.

Tom Hochuli, President of NMDP BioTherapies, highlighted the company's commitment to advancing the cell and gene therapy sector by leveraging over three decades of experience in managing cellular product collections. The enhancements are tailored to provide compliant products and services that support the short and long-term needs of developers.

NMDP BioTherapies facilitates organizations developing next-generation cell and gene therapies by offering access to donors and cord blood units from the NMDP Registry and an extensive collection network. This variety of cell sourcing options aims to enable developers to broaden treatment options for patients with severe or debilitating illnesses.

Key features of the updated suite of products and services include:

• Optimized Standardized GMP Leukopak: This product offers a clinical-grade option with a DMF to streamline regulatory processes. Developers can also opt for modular customizations to align with their specific requirements.
• Expanded RUO Leukopak: This offering caters to various stages of cell therapy development, from early phases to later stages requiring strict adherence to clinical requirements.
• Enhanced CBU Offering: The Cord Blood Bank Alliance has expanded testing capabilities for key characteristics, enabling a more detailed analysis of cord blood bank inventory to identify units suitable for manufacturing allogeneic cell therapies.

Partnering with NMDP BioTherapies provides access to a team of experienced regulatory and cell collection experts, ensuring support for developers throughout the process.

Source: businesswire.com